| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H16ClN3O4 |
| Molecular Weight | 349.769 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(O)=O
InChI
InChIKey=JAPHQRWPEGVNBT-UTUOFQBUSA-N
InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1
| Molecular Formula | C16H16ClN3O4 |
| Molecular Weight | 349.769 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Loracarbef (KT3777) is carbacephem antibiotic structurally identical to cefaclor, except that the sulfur atom of position 1 of the cephem nucleus has been replaced by carbon. It showed good affinity for penicillin-binding proteins. At low concentrations (< 2 mg/L) in vitro, it inhibits Streptococcus pneumoniae, S. pyogenes, beta-haemolytic streptococci groups B, C and G. Proteus mirabilis and Moraxella catarrhalis, including beta-lactamase-producing strains. At therapeutic plasma concentrations it is also active in vitro against most strains of Staphylococcus aureus, S. saprophyticus, Escherichia coli and beta-lactamase-positive and -negative strains of Haemophilus influenzae. Loracarbef has been indicated in the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
In the treatment of adults with pharyngitis, acute bronchitis, tonsillitis and uncomplicated infections of skin and skin structures, loracarbef was studied at a dosage of 200mg twice daily. Patients with acute pneumonia, sinusitis and uncomplicated pyelonephritis were treated with 400mg twice daily in clinical studies. Seven-day courses of 200 or 400mg twice daily were used to treat acute exacerbations of chronic bronchitis (acute superimposed on chronic). A once-daily dose of 200mg is used to treat acute cystitis.
In infants and children, 30 mg/kg in divided doses 12-hourly is used to treat acute otitis media, while 15 mg/kg is recommended for the treatment of pharyngitis, tonsillitis and impetigo.
Dosage should be adjusted in patients with renal impairment whose creatine clearance is below 2.9 L/h (49 ml/min).
Route of Administration:
Oral
